These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 25909788)

  • 1. [The effect of cellex on cognitive and speech impairments in the acute stage of stroke].
    Kovalenko AV; Safronova MN
    Zh Nevrol Psikhiatr Im S S Korsakova; 2015; 115(1):40-44. PubMed ID: 25909788
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Cognitive disorders in stroke patients: the possibilities of pharmacological correction].
    Belskaya GN; Chuprina SE; Vorobyev AA; Gorozha EN; Butorakina TL; Sokolov MA; Izmaylov IA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(5):33-37. PubMed ID: 27240178
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Post-stroke cognitive impairment and the possibility of treatment with cellex].
    Kulesh AA; Shestakov VV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(5):38-42. PubMed ID: 27240179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Cellex in the treatment of patients with acute disturbance of cerebral blood circulation: results of a multicenter comparative open clinical trial].
    Pizova NV; Sokolov MA; Izmaĭlov IA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2014; 114(5):22-6. PubMed ID: 24988954
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Characteristics of ischemic stroke according to hospital register data: a role of neuroreparative therapy].
    Kulesh AA; Shestakov VV; Syromyatnikova LI; Kravtsova EY; Bokov KN; Dementyeva OV; Selezneva SI
    Zh Nevrol Psikhiatr Im S S Korsakova; 2015; 115(7):74-78. PubMed ID: 26356518
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Possibilities of the treatment of speech impairment in the acute stage of ischemic stroke using neuroprotective therapy].
    Belskaya GN; Krilova LG; Sokolov MA; Izmailov IA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2015; 115(9 Pt 2):60-63. PubMed ID: 26525938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Noopept in the treatment of mild cognitive impairment in patients with stroke].
    Amelin AV; Iliukhina AIu; Shmonin AA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(10 Pt 1):44-6. PubMed ID: 22500312
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The NeuroAiD II (MLC901) in vascular cognitive impairment study (NEURITES).
    Chen CL; Ikram K; Anqi Q; Yin WT; Chen A; Venketasubramanian N;
    Cerebrovasc Dis; 2013; 35 Suppl 1():23-9. PubMed ID: 23548916
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel use of modafinal to treat severe physical and cognitive impairment post-stroke.
    Geffen S; Shum K; Tan HM
    Intern Med J; 2013 Mar; 43(3):338. PubMed ID: 23441663
    [No Abstract]   [Full Text] [Related]  

  • 10. [Cognitive impairment in patients poluchennym ischemic stroke in the acute and early recovery periods in the process of neuroprotection low-dose drug cortexin].
    Belova LA; Mashin VV; Abramova VV; Proshin AN; Ovsjannikova AN
    Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(8 Pt 2):40-43. PubMed ID: 27905386
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Cognitive disorders and their correction in patients with ischemic stroke].
    Evzel'man MA; Aleksandrova NA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2013; 113(10):36-9. PubMed ID: 24300803
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The experience of using cellex in treatment of patients with acute ischemic stroke].
    Gaponenko IA; Bakhareva EV; Zolotareva ZM; Zuev GI; Rozhdestvenskiy AS
    Zh Nevrol Psikhiatr Im S S Korsakova; 2018; 118(4):43-47. PubMed ID: 29863691
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical efficacy and pharmacoeconomic characteristics of the neuroprotection with low doses of cortexin in the treatment of acute ischemic stroke].
    Aliferova VM; Dadasheva MN; Doronin BM; Kovalenko AV; Lokshtanova TM; Martynov MIu; Meshkova KS; Salimov KA; Stakhovskaia LV; Chefranova ZhIu; Shamalov NA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2014; 114(4):41-6. PubMed ID: 24874316
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Cognitive disorders in the early rehabilitation period of ischemic stroke and possibilities of their treatment with neuromidin].
    Pustokhanova LV; Morozova EM
    Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(4 Pt 2):23-7. PubMed ID: 23120773
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Wisconsin card sorting test as a measure of executive function impairments in stroke patients.
    Jodzio K; Biechowska D
    Appl Neuropsychol; 2010 Oct; 17(4):267-77. PubMed ID: 21154040
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [New possibilities of neuroprotection in the treatment of ischemic stroke].
    Skoromets AA; Stakhovskaia LV; Belkin AA; Shekhovtsova KV; Kerbikov OB; Burenchev DV; Gavrilova OV; Skvortsova VI
    Zh Nevrol Psikhiatr Im S S Korsakova; 2008; Suppl 22():32-8. PubMed ID: 19431244
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term treatment with citicoline may improve poststroke vascular cognitive impairment.
    Alvarez-Sabín J; Ortega G; Jacas C; Santamarina E; Maisterra O; Ribo M; Molina C; Quintana M; Román GC
    Cerebrovasc Dis; 2013; 35(2):146-54. PubMed ID: 23406981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Heterogeneity of cognitive disorders in the acute stage of the first ischemic carotid stroke].
    Kulesh AA; Shestakov VV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2012; 112(8 Pt 2):31-4. PubMed ID: 23390652
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The effect of cerebrolysin in dosage 50 ml on the volume of lesion in ischemic stroke].
    Shamalov NA; Stakhovskaia LV; Burenchev DV; Kichuk IV; Tvorogova TV; Botsina AIu; Smychkov AS; Kerbikov OB; Moessler H; Novak P; Skvortsova VI
    Zh Nevrol Psikhiatr Im S S Korsakova; 2010; 110(12 Pt 2):34-7. PubMed ID: 21626816
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comment on: "Perispinal Etanercept for Post-Stroke Neurological and Cognitive Dysfunction: Scientific Rationale and Current Evidence".
    Whitlock DR
    CNS Drugs; 2014 Dec; 28(12):1205-6. PubMed ID: 25373628
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.